ATGAM

Product Overview

About ATGAM

ATGAM is a medication containing LYMPHOCYTE IMMUNOGLOBULIN ANTI-THYMOCYTE GLOBULIN (EQUINE) as its active ingredient. It is used in the treatment of acute graft-versus-host disease (GVHD) and as an immunosuppressive agent in the prevention of renal transplant rejection.

Key Benefits & Uses

• Treatment of acute graft-versus-host disease (GVHD)
• Prevention of renal transplant rejection

Active Ingredient & Action

LYMPHOCYTE IMMUNOGLOBULIN ANTI-THYMOCYTE GLOBULIN (EQUINE) is a polyclonal antibody that selectively depletes T-lymphocytes, thereby reducing the immune response and preventing graft rejection. It works by binding to the CD3 receptor on T-lymphocytes, leading to their depletion and reduced immune activity.

Important Notes

ATGAM should only be administered under the guidance of a qualified healthcare professional. Patients with a history of allergic reactions to horse-derived products or immunoglobulins should not receive ATGAM. It is essential to monitor patients for signs of infection, bleeding, or other adverse effects during treatment with ATGAM.